Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Models, Statistical | 9 | 2016 | 160 | 2.060 |
Why?
|
Diet | 15 | 2016 | 348 | 1.890 |
Why?
|
Nutrition Assessment | 8 | 2018 | 54 | 1.810 |
Why?
|
Energy Intake | 10 | 2018 | 120 | 1.710 |
Why?
|
Population Surveillance | 2 | 2019 | 119 | 1.270 |
Why?
|
Dietary Supplements | 6 | 2019 | 170 | 1.070 |
Why?
|
Survivors | 7 | 2016 | 145 | 1.060 |
Why?
|
Nutrition Surveys | 7 | 2018 | 133 | 1.030 |
Why?
|
Diet Surveys | 10 | 2015 | 56 | 0.960 |
Why?
|
Humans | 92 | 2019 | 29013 | 0.960 |
Why?
|
Female | 71 | 2019 | 18114 | 0.910 |
Why?
|
Nutrition Policy | 5 | 2018 | 33 | 0.910 |
Why?
|
Aged | 47 | 2018 | 9462 | 0.870 |
Why?
|
Male | 69 | 2019 | 17768 | 0.850 |
Why?
|
Vitamin D | 9 | 2015 | 170 | 0.810 |
Why?
|
Adult | 34 | 2019 | 8391 | 0.780 |
Why?
|
Eating | 5 | 2019 | 73 | 0.750 |
Why?
|
United States | 23 | 2018 | 3604 | 0.750 |
Why?
|
Energy Metabolism | 6 | 2013 | 139 | 0.730 |
Why?
|
Biomedical Research | 3 | 2018 | 153 | 0.710 |
Why?
|
Dietetics | 2 | 2018 | 4 | 0.690 |
Why?
|
Statistical Distributions | 2 | 2010 | 5 | 0.690 |
Why?
|
Middle Aged | 34 | 2018 | 10805 | 0.680 |
Why?
|
Papillomavirus Vaccines | 1 | 2019 | 36 | 0.680 |
Why?
|
Nutrition Disorders | 1 | 2018 | 12 | 0.670 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 52 | 0.660 |
Why?
|
Patient Compliance | 3 | 2018 | 208 | 0.660 |
Why?
|
Diet, Sodium-Restricted | 1 | 2018 | 20 | 0.650 |
Why?
|
Vaccination | 1 | 2019 | 123 | 0.640 |
Why?
|
Sodium, Dietary | 1 | 2018 | 24 | 0.640 |
Why?
|
African Americans | 7 | 2017 | 1373 | 0.620 |
Why?
|
Research Design | 2 | 2019 | 285 | 0.620 |
Why?
|
Vitamin D Deficiency | 6 | 2014 | 89 | 0.610 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 63 | 0.600 |
Why?
|
Health | 1 | 2016 | 13 | 0.580 |
Why?
|
Health Education | 1 | 2017 | 121 | 0.580 |
Why?
|
Nutritional Requirements | 3 | 2019 | 13 | 0.560 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 373 | 0.550 |
Why?
|
Health Promotion | 3 | 2016 | 220 | 0.540 |
Why?
|
Diabetes Mellitus, Type 1 | 4 | 2019 | 180 | 0.520 |
Why?
|
Colorectal Neoplasms | 3 | 2012 | 208 | 0.510 |
Why?
|
Head and Neck Neoplasms | 4 | 2016 | 117 | 0.490 |
Why?
|
Colonoscopy | 3 | 2012 | 41 | 0.470 |
Why?
|
Self Disclosure | 3 | 2015 | 23 | 0.470 |
Why?
|
Epidemiologic Measurements | 1 | 2013 | 2 | 0.470 |
Why?
|
Mass Screening | 2 | 2012 | 223 | 0.460 |
Why?
|
Exercise | 4 | 2019 | 587 | 0.460 |
Why?
|
Breast Neoplasms | 3 | 2018 | 666 | 0.460 |
Why?
|
Hypertension | 2 | 2018 | 899 | 0.450 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2015 | 14 | 0.450 |
Why?
|
Aged, 80 and over | 16 | 2018 | 3712 | 0.450 |
Why?
|
Interviews as Topic | 5 | 2014 | 249 | 0.450 |
Why?
|
Medicaid | 2 | 2012 | 83 | 0.440 |
Why?
|
Cross-Sectional Studies | 12 | 2018 | 1353 | 0.440 |
Why?
|
Reproducibility of Results | 8 | 2018 | 724 | 0.420 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2016 | 173 | 0.420 |
Why?
|
Insurance Coverage | 1 | 2012 | 74 | 0.410 |
Why?
|
Adolescent | 13 | 2019 | 3248 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 337 | 0.390 |
Why?
|
Cohort Studies | 9 | 2019 | 1674 | 0.390 |
Why?
|
Data Interpretation, Statistical | 3 | 2018 | 103 | 0.390 |
Why?
|
Feeding Behavior | 3 | 2008 | 159 | 0.390 |
Why?
|
Child | 11 | 2019 | 2209 | 0.390 |
Why?
|
Neoplasms | 5 | 2019 | 608 | 0.380 |
Why?
|
Risk Factors | 16 | 2017 | 3509 | 0.380 |
Why?
|
Young Adult | 8 | 2019 | 2398 | 0.380 |
Why?
|
Social Class | 2 | 2007 | 71 | 0.370 |
Why?
|
Models, Biological | 2 | 2009 | 372 | 0.370 |
Why?
|
Geriatric Assessment | 8 | 2018 | 355 | 0.370 |
Why?
|
Yoga | 3 | 2018 | 41 | 0.360 |
Why?
|
Smoking | 5 | 2016 | 427 | 0.360 |
Why?
|
Diet Records | 5 | 2016 | 31 | 0.360 |
Why?
|
Risk | 2 | 2009 | 289 | 0.360 |
Why?
|
Vegetables | 4 | 2017 | 35 | 0.350 |
Why?
|
Registries | 4 | 2019 | 278 | 0.350 |
Why?
|
Biometry | 3 | 2016 | 12 | 0.350 |
Why?
|
Food Supply | 3 | 2018 | 52 | 0.350 |
Why?
|
Socioeconomic Factors | 5 | 2018 | 385 | 0.340 |
Why?
|
European Continental Ancestry Group | 8 | 2017 | 1131 | 0.340 |
Why?
|
Mental Recall | 9 | 2015 | 52 | 0.340 |
Why?
|
Prospective Studies | 12 | 2018 | 2010 | 0.330 |
Why?
|
Follow-Up Studies | 6 | 2018 | 2106 | 0.330 |
Why?
|
Brain Ischemia | 1 | 2009 | 136 | 0.320 |
Why?
|
Vitamins | 3 | 2018 | 58 | 0.310 |
Why?
|
Dietary Carbohydrates | 2 | 2019 | 21 | 0.310 |
Why?
|
Dietary Fats | 2 | 2006 | 108 | 0.300 |
Why?
|
Age Factors | 6 | 2018 | 1105 | 0.300 |
Why?
|
Circadian Rhythm | 1 | 2007 | 43 | 0.300 |
Why?
|
Brain Injuries | 2 | 2018 | 94 | 0.290 |
Why?
|
Prostatic Neoplasms | 4 | 2012 | 441 | 0.290 |
Why?
|
Sex Factors | 5 | 2011 | 626 | 0.290 |
Why?
|
Mobility Limitation | 4 | 2017 | 187 | 0.280 |
Why?
|
Child, Preschool | 8 | 2018 | 1164 | 0.280 |
Why?
|
Patient Participation | 2 | 2019 | 62 | 0.270 |
Why?
|
Mammary Glands, Animal | 3 | 2016 | 46 | 0.270 |
Why?
|
Abdominal Injuries | 1 | 2005 | 33 | 0.270 |
Why?
|
Patient Admission | 1 | 2005 | 53 | 0.270 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2014 | 1374 | 0.260 |
Why?
|
Pelvis | 1 | 2005 | 61 | 0.260 |
Why?
|
Wounds, Nonpenetrating | 1 | 2005 | 90 | 0.260 |
Why?
|
Body Mass Index | 8 | 2019 | 862 | 0.250 |
Why?
|
Analysis of Variance | 4 | 2018 | 454 | 0.250 |
Why?
|
Parathyroid Hormone | 3 | 2012 | 38 | 0.240 |
Why?
|
Brain | 2 | 2018 | 930 | 0.240 |
Why?
|
Depression | 3 | 2016 | 378 | 0.240 |
Why?
|
Craniocerebral Trauma | 2 | 2015 | 56 | 0.240 |
Why?
|
Health Personnel | 2 | 2017 | 111 | 0.240 |
Why?
|
Cardiovascular Diseases | 4 | 2016 | 1007 | 0.230 |
Why?
|
Cognition Disorders | 3 | 2012 | 389 | 0.230 |
Why?
|
Computer Simulation | 2 | 2016 | 202 | 0.220 |
Why?
|
Retrospective Studies | 9 | 2018 | 3107 | 0.220 |
Why?
|
Lung Neoplasms | 2 | 2018 | 384 | 0.220 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 546 | 0.220 |
Why?
|
Soybean Proteins | 2 | 2016 | 64 | 0.220 |
Why?
|
Geriatrics | 2 | 2016 | 94 | 0.210 |
Why?
|
Health Expenditures | 1 | 2002 | 61 | 0.210 |
Why?
|
Radiation Injuries, Experimental | 2 | 2018 | 33 | 0.200 |
Why?
|
Incidence | 5 | 2017 | 1105 | 0.200 |
Why?
|
Physical Fitness | 2 | 2012 | 119 | 0.200 |
Why?
|
Child Nutritional Physiological Phenomena | 2 | 2018 | 11 | 0.200 |
Why?
|
Dietary Fiber | 2 | 2013 | 19 | 0.200 |
Why?
|
Isoflavones | 2 | 2013 | 65 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 1 | 2005 | 871 | 0.190 |
Why?
|
Diet, Fat-Restricted | 2 | 2014 | 30 | 0.190 |
Why?
|
Mental Health | 3 | 2016 | 102 | 0.190 |
Why?
|
Treatment Outcome | 7 | 2018 | 3099 | 0.190 |
Why?
|
Pilot Projects | 8 | 2018 | 469 | 0.180 |
Why?
|
Pennsylvania | 6 | 2017 | 77 | 0.180 |
Why?
|
Patient Care Management | 2 | 2016 | 17 | 0.180 |
Why?
|
Tennessee | 6 | 2017 | 97 | 0.180 |
Why?
|
Reference Values | 2 | 2018 | 224 | 0.180 |
Why?
|
Gene Expression | 2 | 2018 | 332 | 0.180 |
Why?
|
Patients | 2 | 2017 | 46 | 0.180 |
Why?
|
Risk Assessment | 3 | 2018 | 1300 | 0.180 |
Why?
|
Psychometrics | 2 | 2018 | 129 | 0.180 |
Why?
|
DNA Damage | 2 | 2018 | 88 | 0.180 |
Why?
|
Independent Living | 2 | 2017 | 77 | 0.180 |
Why?
|
Health Services Accessibility | 2 | 2012 | 231 | 0.170 |
Why?
|
Urban Population | 2 | 2017 | 79 | 0.170 |
Why?
|
Logistic Models | 5 | 2011 | 725 | 0.170 |
Why?
|
Regression Analysis | 3 | 2009 | 272 | 0.170 |
Why?
|
Epidemiologic Research Design | 1 | 2018 | 4 | 0.170 |
Why?
|
Beverages | 2 | 2015 | 19 | 0.170 |
Why?
|
Trace Elements | 1 | 2018 | 7 | 0.170 |
Why?
|
Cranial Irradiation | 2 | 2017 | 84 | 0.170 |
Why?
|
Mammary Glands, Human | 1 | 2018 | 15 | 0.170 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 24 | 0.170 |
Why?
|
Air Pollution | 1 | 2018 | 16 | 0.170 |
Why?
|
Environmental Monitoring | 1 | 2018 | 26 | 0.170 |
Why?
|
Principal Component Analysis | 1 | 2018 | 60 | 0.170 |
Why?
|
Diet, Mediterranean | 1 | 2018 | 23 | 0.170 |
Why?
|
Fibronectins | 1 | 2018 | 34 | 0.160 |
Why?
|
Carboplatin | 1 | 2018 | 40 | 0.160 |
Why?
|
Income | 1 | 2018 | 51 | 0.160 |
Why?
|
Paclitaxel | 1 | 2018 | 50 | 0.160 |
Why?
|
Health Status | 4 | 2015 | 368 | 0.160 |
Why?
|
Brain Neoplasms | 3 | 2013 | 587 | 0.160 |
Why?
|
Blood Cells | 1 | 2018 | 9 | 0.160 |
Why?
|
Nutritional Status | 1 | 2018 | 68 | 0.160 |
Why?
|
Cross-Over Studies | 1 | 2018 | 93 | 0.160 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2018 | 71 | 0.160 |
Why?
|
Health Surveys | 3 | 2013 | 191 | 0.160 |
Why?
|
Cerebrovascular Circulation | 1 | 2018 | 95 | 0.160 |
Why?
|
Environmental Exposure | 1 | 2018 | 86 | 0.160 |
Why?
|
Gardening | 1 | 2017 | 2 | 0.160 |
Why?
|
Activities of Daily Living | 2 | 2016 | 237 | 0.160 |
Why?
|
Atherosclerosis | 2 | 2017 | 691 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 93 | 0.150 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 94 | 0.150 |
Why?
|
Hemorrhage | 2 | 2015 | 90 | 0.150 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 145 | 0.150 |
Why?
|
Decision Making | 2 | 2012 | 180 | 0.150 |
Why?
|
Awareness | 1 | 2017 | 28 | 0.150 |
Why?
|
Environment | 1 | 2017 | 51 | 0.150 |
Why?
|
Animals | 12 | 2018 | 7297 | 0.150 |
Why?
|
Amino Acids | 1 | 2017 | 41 | 0.150 |
Why?
|
Internet | 1 | 2018 | 156 | 0.150 |
Why?
|
Sensitivity and Specificity | 5 | 2014 | 531 | 0.150 |
Why?
|
Program Evaluation | 1 | 2017 | 175 | 0.150 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 48 | 0.150 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2016 | 32 | 0.150 |
Why?
|
Insulin Resistance | 2 | 2011 | 449 | 0.150 |
Why?
|
Radiation Injuries | 1 | 2017 | 67 | 0.140 |
Why?
|
Extracellular Matrix | 1 | 2018 | 226 | 0.140 |
Why?
|
Physician's Role | 1 | 2016 | 38 | 0.140 |
Why?
|
Cognition | 3 | 2016 | 524 | 0.140 |
Why?
|
Rural Health | 2 | 2007 | 43 | 0.140 |
Why?
|
Fellowships and Scholarships | 1 | 2016 | 50 | 0.140 |
Why?
|
Prognosis | 4 | 2014 | 1362 | 0.140 |
Why?
|
Epilepsy | 1 | 2017 | 59 | 0.140 |
Why?
|
Meditation | 2 | 2016 | 22 | 0.140 |
Why?
|
Sexual Maturation | 1 | 2016 | 26 | 0.140 |
Why?
|
Medical Oncology | 1 | 2016 | 70 | 0.140 |
Why?
|
Cotinine | 3 | 2015 | 45 | 0.140 |
Why?
|
Residence Characteristics | 1 | 2017 | 177 | 0.140 |
Why?
|
Diabetic Angiopathies | 1 | 2016 | 137 | 0.140 |
Why?
|
Homebound Persons | 1 | 2015 | 8 | 0.140 |
Why?
|
Proportional Hazards Models | 5 | 2018 | 706 | 0.130 |
Why?
|
Cholecalciferol | 1 | 2015 | 21 | 0.130 |
Why?
|
Food Services | 1 | 2015 | 18 | 0.130 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2016 | 41 | 0.130 |
Why?
|
Time Factors | 6 | 2018 | 1997 | 0.130 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2015 | 9 | 0.130 |
Why?
|
Spinal Cord Injuries | 1 | 2015 | 32 | 0.130 |
Why?
|
Wheelchairs | 1 | 2014 | 1 | 0.130 |
Why?
|
Decontamination | 1 | 2014 | 2 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 142 | 0.130 |
Why?
|
Disinfection | 1 | 2014 | 5 | 0.130 |
Why?
|
Hypotension | 1 | 2015 | 47 | 0.130 |
Why?
|
Muscle Strength | 2 | 2012 | 139 | 0.130 |
Why?
|
Neuropsychological Tests | 3 | 2012 | 378 | 0.130 |
Why?
|
Cell Differentiation | 2 | 2016 | 436 | 0.130 |
Why?
|
Injury Severity Score | 3 | 2015 | 115 | 0.130 |
Why?
|
Fruit | 2 | 2012 | 53 | 0.130 |
Why?
|
Caregivers | 1 | 2016 | 94 | 0.130 |
Why?
|
Rural Population | 4 | 2013 | 244 | 0.120 |
Why?
|
Polypharmacy | 1 | 2014 | 20 | 0.120 |
Why?
|
Cross Infection | 1 | 2014 | 46 | 0.120 |
Why?
|
Disabled Persons | 2 | 2012 | 83 | 0.120 |
Why?
|
Food | 2 | 2015 | 41 | 0.120 |
Why?
|
Probability | 2 | 2005 | 150 | 0.120 |
Why?
|
United States Department of Agriculture | 1 | 2013 | 3 | 0.120 |
Why?
|
Food Handling | 1 | 2013 | 5 | 0.120 |
Why?
|
Academic Medical Centers | 1 | 2015 | 150 | 0.120 |
Why?
|
Motor Activity | 2 | 2013 | 310 | 0.120 |
Why?
|
Puberty | 1 | 2013 | 8 | 0.120 |
Why?
|
Pain, Postoperative | 1 | 2016 | 173 | 0.120 |
Why?
|
Accidental Falls | 1 | 2015 | 204 | 0.120 |
Why?
|
Soybeans | 1 | 2013 | 25 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 161 | 0.120 |
Why?
|
Hematologic Diseases | 1 | 2013 | 23 | 0.110 |
Why?
|
Dacarbazine | 1 | 2013 | 29 | 0.110 |
Why?
|
Shock | 1 | 2013 | 28 | 0.110 |
Why?
|
Seasons | 3 | 2011 | 84 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 40 | 0.110 |
Why?
|
Models, Psychological | 1 | 2013 | 22 | 0.110 |
Why?
|
Markov Chains | 1 | 2013 | 25 | 0.110 |
Why?
|
Poverty | 2 | 2011 | 98 | 0.110 |
Why?
|
Smoking Cessation | 2 | 2012 | 118 | 0.110 |
Why?
|
Hyperparathyroidism | 1 | 2012 | 7 | 0.110 |
Why?
|
Indians, North American | 3 | 2007 | 108 | 0.110 |
Why?
|
Affect | 1 | 2013 | 63 | 0.110 |
Why?
|
Survival Rate | 2 | 2012 | 795 | 0.110 |
Why?
|
Prevalence | 3 | 2011 | 892 | 0.110 |
Why?
|
Nonverbal Communication | 1 | 2012 | 4 | 0.110 |
Why?
|
Time | 1 | 2012 | 21 | 0.110 |
Why?
|
Macaca mulatta | 3 | 2018 | 322 | 0.110 |
Why?
|
Therapeutic Touch | 2 | 2012 | 10 | 0.110 |
Why?
|
Hip Fractures | 1 | 2012 | 30 | 0.110 |
Why?
|
Empathy | 1 | 2012 | 17 | 0.110 |
Why?
|
Touch | 1 | 2012 | 35 | 0.110 |
Why?
|
Autonomic Nervous System | 1 | 2012 | 42 | 0.100 |
Why?
|
Cholinesterase Inhibitors | 1 | 2012 | 29 | 0.100 |
Why?
|
Indans | 1 | 2012 | 25 | 0.100 |
Why?
|
Glasgow Coma Scale | 2 | 2015 | 27 | 0.100 |
Why?
|
Glioblastoma | 1 | 2013 | 143 | 0.100 |
Why?
|
Infant | 4 | 2018 | 967 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 325 | 0.100 |
Why?
|
Longitudinal Studies | 4 | 2016 | 708 | 0.100 |
Why?
|
Medication Adherence | 1 | 2013 | 144 | 0.100 |
Why?
|
Language Tests | 1 | 2011 | 4 | 0.100 |
Why?
|
Intelligence Tests | 1 | 2011 | 9 | 0.100 |
Why?
|
Monte Carlo Method | 1 | 2010 | 17 | 0.100 |
Why?
|
Trauma Centers | 2 | 2015 | 84 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2010 | 38 | 0.100 |
Why?
|
Iron, Dietary | 1 | 2010 | 11 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2010 | 8 | 0.100 |
Why?
|
Calcium, Dietary | 1 | 2010 | 23 | 0.100 |
Why?
|
Vitamin A | 1 | 2010 | 19 | 0.100 |
Why?
|
Disease Management | 1 | 2011 | 114 | 0.100 |
Why?
|
Piperidines | 1 | 2012 | 125 | 0.100 |
Why?
|
North Carolina | 6 | 2012 | 1422 | 0.100 |
Why?
|
Sunscreening Agents | 1 | 2010 | 11 | 0.100 |
Why?
|
Colonic Neoplasms | 1 | 2011 | 63 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2011 | 163 | 0.100 |
Why?
|
Adenoma | 1 | 2011 | 35 | 0.100 |
Why?
|
Biostatistics | 1 | 2010 | 8 | 0.100 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2010 | 1 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 481 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2010 | 20 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2012 | 149 | 0.090 |
Why?
|
Postoperative Complications | 1 | 2015 | 670 | 0.090 |
Why?
|
Feasibility Studies | 4 | 2015 | 262 | 0.090 |
Why?
|
Cancer Vaccines | 1 | 2010 | 21 | 0.090 |
Why?
|
Nutritional Physiological Phenomena | 2 | 2007 | 17 | 0.090 |
Why?
|
Memory | 1 | 2012 | 187 | 0.090 |
Why?
|
Heart Rate | 1 | 2012 | 315 | 0.090 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2010 | 33 | 0.090 |
Why?
|
Patient Selection | 2 | 2012 | 257 | 0.090 |
Why?
|
Algorithms | 2 | 2010 | 461 | 0.090 |
Why?
|
Comorbidity | 4 | 2013 | 539 | 0.090 |
Why?
|
Hand Strength | 1 | 2010 | 85 | 0.090 |
Why?
|
Aging | 5 | 2017 | 880 | 0.090 |
Why?
|
Educational Status | 2 | 2007 | 162 | 0.090 |
Why?
|
Quality of Life | 2 | 2012 | 815 | 0.090 |
Why?
|
Healthcare Disparities | 1 | 2011 | 153 | 0.090 |
Why?
|
Melanoma | 1 | 2010 | 148 | 0.090 |
Why?
|
Fibrinogen | 1 | 2008 | 42 | 0.080 |
Why?
|
Body Water | 2 | 2009 | 8 | 0.080 |
Why?
|
Maryland | 2 | 2009 | 26 | 0.080 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2008 | 46 | 0.080 |
Why?
|
Walking | 1 | 2010 | 177 | 0.080 |
Why?
|
Contraceptives, Oral | 1 | 2008 | 20 | 0.080 |
Why?
|
Glucose Tolerance Test | 1 | 2008 | 125 | 0.080 |
Why?
|
Counseling | 2 | 2012 | 85 | 0.080 |
Why?
|
Hospitalization | 1 | 2011 | 417 | 0.080 |
Why?
|
Leukemia | 1 | 2008 | 36 | 0.080 |
Why?
|
Deuterium Oxide | 1 | 2007 | 1 | 0.080 |
Why?
|
Calorimetry | 1 | 2007 | 3 | 0.080 |
Why?
|
Estrogens | 1 | 2008 | 162 | 0.080 |
Why?
|
Macaca fascicularis | 3 | 2016 | 389 | 0.080 |
Why?
|
African Continental Ancestry Group | 3 | 2014 | 350 | 0.080 |
Why?
|
Tunica Intima | 1 | 2007 | 59 | 0.080 |
Why?
|
Adenocarcinoma | 1 | 2010 | 301 | 0.080 |
Why?
|
Carotid Artery, Common | 1 | 2007 | 37 | 0.080 |
Why?
|
Adenomatous Polyps | 1 | 2007 | 9 | 0.080 |
Why?
|
Ganglionic Stimulants | 1 | 2007 | 7 | 0.080 |
Why?
|
Body Size | 1 | 2007 | 31 | 0.080 |
Why?
|
Ovarian Neoplasms | 1 | 2008 | 87 | 0.070 |
Why?
|
Adaptation, Psychological | 1 | 2008 | 125 | 0.070 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 2 | 2018 | 2 | 0.070 |
Why?
|
Insulin | 1 | 2008 | 346 | 0.070 |
Why?
|
Genes, APC | 1 | 2006 | 1 | 0.070 |
Why?
|
Intestinal Polyps | 1 | 2006 | 4 | 0.070 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2007 | 53 | 0.070 |
Why?
|
Running | 1 | 2006 | 16 | 0.070 |
Why?
|
Obesity | 3 | 2011 | 1062 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2013 | 636 | 0.070 |
Why?
|
Carotid Artery Diseases | 1 | 2007 | 109 | 0.070 |
Why?
|
Physical Conditioning, Animal | 1 | 2006 | 32 | 0.070 |
Why?
|
Dietary Sucrose | 1 | 2006 | 11 | 0.070 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2006 | 52 | 0.070 |
Why?
|
Blood Glucose | 1 | 2008 | 465 | 0.070 |
Why?
|
Tobacco Use Disorder | 1 | 2007 | 76 | 0.070 |
Why?
|
Role | 1 | 2005 | 5 | 0.070 |
Why?
|
Blood Cell Count | 2 | 2018 | 26 | 0.070 |
Why?
|
Crack Cocaine | 1 | 2005 | 4 | 0.070 |
Why?
|
HIV Seropositivity | 1 | 2005 | 13 | 0.070 |
Why?
|
Substance Abuse, Intravenous | 1 | 2005 | 27 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2014 | 784 | 0.070 |
Why?
|
Overweight | 1 | 2007 | 256 | 0.070 |
Why?
|
Inflammation | 1 | 2008 | 503 | 0.070 |
Why?
|
Triglycerides | 2 | 2016 | 214 | 0.070 |
Why?
|
Risk-Taking | 1 | 2005 | 91 | 0.060 |
Why?
|
Nicotine | 1 | 2007 | 157 | 0.060 |
Why?
|
Personality Assessment | 1 | 2004 | 6 | 0.060 |
Why?
|
Social Desirability | 1 | 2004 | 8 | 0.060 |
Why?
|
Body Image | 1 | 2004 | 13 | 0.060 |
Why?
|
Cocaine-Related Disorders | 1 | 2005 | 106 | 0.060 |
Why?
|
Independent Practice Associations | 1 | 2003 | 3 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 1218 | 0.060 |
Why?
|
Managed Care Programs | 1 | 2003 | 38 | 0.060 |
Why?
|
Documentation | 1 | 2003 | 32 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2016 | 436 | 0.060 |
Why?
|
Pain Measurement | 2 | 2016 | 360 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2005 | 429 | 0.050 |
Why?
|
Life Style | 1 | 2004 | 363 | 0.050 |
Why?
|
Demography | 2 | 2016 | 104 | 0.050 |
Why?
|
Morbidity | 2 | 2011 | 91 | 0.050 |
Why?
|
Body Weight | 2 | 2017 | 290 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 248 | 0.050 |
Why?
|
Ethnic Groups | 2 | 2017 | 440 | 0.050 |
Why?
|
Linear Models | 2 | 2012 | 425 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 292 | 0.040 |
Why?
|
Validation Studies as Topic | 1 | 2018 | 8 | 0.040 |
Why?
|
Mice | 3 | 2010 | 2368 | 0.040 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2018 | 3 | 0.040 |
Why?
|
Nutritive Value | 1 | 2018 | 7 | 0.040 |
Why?
|
Air Pollutants | 1 | 2018 | 19 | 0.040 |
Why?
|
Haplorhini | 1 | 2018 | 64 | 0.040 |
Why?
|
Micronucleus Tests | 1 | 2018 | 3 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 21 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 76 | 0.040 |
Why?
|
Thorax | 1 | 2018 | 27 | 0.040 |
Why?
|
Body Composition | 2 | 2012 | 365 | 0.040 |
Why?
|
Disease Progression | 2 | 2012 | 572 | 0.040 |
Why?
|
Lung Injury | 1 | 2018 | 64 | 0.040 |
Why?
|
Sex Distribution | 2 | 2009 | 185 | 0.040 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 4 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 98 | 0.040 |
Why?
|
Education | 1 | 2016 | 30 | 0.040 |
Why?
|
Telemedicine | 1 | 2018 | 73 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 53 | 0.040 |
Why?
|
Lipoproteins, LDL | 1 | 2016 | 77 | 0.040 |
Why?
|
Phytoestrogens | 1 | 2016 | 16 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2017 | 118 | 0.040 |
Why?
|
Neuronal Plasticity | 1 | 2017 | 81 | 0.040 |
Why?
|
Physical Examination | 1 | 2016 | 82 | 0.040 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 164 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2016 | 15 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2016 | 89 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 172 | 0.030 |
Why?
|
Diet Therapy | 1 | 2015 | 13 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2015 | 21 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 155 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 168 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2015 | 165 | 0.030 |
Why?
|
Data Collection | 1 | 2015 | 163 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 401 | 0.030 |
Why?
|
Curriculum | 1 | 2016 | 196 | 0.030 |
Why?
|
Public Health | 1 | 2015 | 72 | 0.030 |
Why?
|
Canada | 1 | 2014 | 48 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2015 | 72 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 156 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2016 | 519 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2014 | 70 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 73 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2014 | 106 | 0.030 |
Why?
|
Telephone | 1 | 2014 | 48 | 0.030 |
Why?
|
Adiposity | 1 | 2015 | 191 | 0.030 |
Why?
|
Length of Stay | 1 | 2015 | 291 | 0.030 |
Why?
|
Radiography | 1 | 2015 | 353 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 46 | 0.030 |
Why?
|
Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
Louisiana | 1 | 2013 | 12 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2015 | 595 | 0.030 |
Why?
|
Medicare | 1 | 2014 | 185 | 0.030 |
Why?
|
Age Distribution | 1 | 2013 | 197 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2013 | 59 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 169 | 0.030 |
Why?
|
Software | 1 | 2013 | 109 | 0.030 |
Why?
|
Reading | 1 | 2012 | 5 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 129 | 0.030 |
Why?
|
Love | 1 | 2012 | 4 | 0.030 |
Why?
|
Relaxation | 1 | 2012 | 9 | 0.030 |
Why?
|
Respiratory Rate | 1 | 2012 | 12 | 0.030 |
Why?
|
Patient Preference | 1 | 2012 | 38 | 0.030 |
Why?
|
Digital Rectal Examination | 1 | 2012 | 10 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 23 | 0.030 |
Why?
|
Extremities | 1 | 2012 | 48 | 0.030 |
Why?
|
Rest | 1 | 2012 | 49 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2012 | 61 | 0.030 |
Why?
|
Outpatients | 1 | 2012 | 49 | 0.030 |
Why?
|
Self Administration | 1 | 2013 | 296 | 0.030 |
Why?
|
Nursing Assessment | 1 | 2011 | 11 | 0.030 |
Why?
|
Executive Function | 1 | 2012 | 54 | 0.030 |
Why?
|
Cause of Death | 1 | 2012 | 219 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2012 | 176 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2013 | 514 | 0.030 |
Why?
|
Students | 1 | 2013 | 167 | 0.020 |
Why?
|
Biopsy | 1 | 2012 | 241 | 0.020 |
Why?
|
Blood Pressure | 1 | 2015 | 803 | 0.020 |
Why?
|
Health Behavior | 1 | 2012 | 212 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 92 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 573 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 16 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2013 | 249 | 0.020 |
Why?
|
CD4-CD8 Ratio | 1 | 2010 | 2 | 0.020 |
Why?
|
Orchiectomy | 1 | 2010 | 12 | 0.020 |
Why?
|
Ultraviolet Rays | 1 | 2010 | 46 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2011 | 210 | 0.020 |
Why?
|
Androgens | 1 | 2010 | 22 | 0.020 |
Why?
|
Fishes | 1 | 2009 | 7 | 0.020 |
Why?
|
Mercury | 1 | 2009 | 8 | 0.020 |
Why?
|
Physicians | 1 | 2012 | 134 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 154 | 0.020 |
Why?
|
District of Columbia | 1 | 2009 | 4 | 0.020 |
Why?
|
Sarcoma | 1 | 2010 | 56 | 0.020 |
Why?
|
Basal Metabolism | 1 | 2009 | 8 | 0.020 |
Why?
|
Oxygen Isotopes | 1 | 2009 | 7 | 0.020 |
Why?
|
Deuterium | 1 | 2009 | 9 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 446 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2010 | 425 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 34 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 462 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2008 | 93 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 298 | 0.020 |
Why?
|
Random Allocation | 1 | 2008 | 212 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2010 | 206 | 0.020 |
Why?
|
Psychological Tests | 1 | 2008 | 33 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2010 | 680 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 711 | 0.020 |
Why?
|
Endometrium | 1 | 2008 | 120 | 0.020 |
Why?
|
Observation | 1 | 2007 | 23 | 0.020 |
Why?
|
Carotid Artery, Internal | 1 | 2007 | 29 | 0.020 |
Why?
|
Qualitative Research | 1 | 2008 | 142 | 0.020 |
Why?
|
Acute Disease | 1 | 2008 | 239 | 0.020 |
Why?
|
Administration, Intranasal | 1 | 2007 | 30 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2007 | 51 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2010 | 980 | 0.020 |
Why?
|
Corticosterone | 1 | 2006 | 9 | 0.020 |
Why?
|
Hematocrit | 1 | 2006 | 23 | 0.020 |
Why?
|
Postmenopause | 1 | 2008 | 397 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 246 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2008 | 222 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2008 | 207 | 0.020 |
Why?
|
Models, Animal | 1 | 2006 | 160 | 0.020 |
Why?
|
Massachusetts | 1 | 2005 | 28 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2006 | 80 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2005 | 97 | 0.020 |
Why?
|
Vermont | 1 | 2003 | 2 | 0.020 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2003 | 5 | 0.010 |
Why?
|
Efficiency, Organizational | 1 | 2003 | 18 | 0.010 |
Why?
|
Reminder Systems | 1 | 2003 | 11 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2003 | 45 | 0.010 |
Why?
|
Health Services Research | 1 | 2003 | 78 | 0.010 |
Why?
|